ImmuPharma (LON:IMM) Stock Price Up 24.1% - What's Next?

Key Points

• ImmuPharma's stock price surged by 24.1% during mid-day trading, reaching GBX 10 ($0.14) after closing at GBX 8.06 ($0.11).
• The company reported a significant increase in trading volume, with approximately 42.5 million shares changing hands, which is a 464% rise from the average daily volume.
• ImmuPharma has a market capitalization of £53.97 million and is focused on developing peptide-based therapeutics for autoimmune diseases.

ImmuPharma plc (LON:IMM - Get Free Report)'s share price shot up 24.1% during trading on Tuesday . The stock traded as high as GBX 10.50 ($0.14) and last traded at GBX 10 ($0.14). 42,505,293 shares traded hands during trading, an increase of 464% from the average session volume of 7,534,203 shares. The stock had previously closed at GBX 8.06 ($0.11).

ImmuPharma Trading Up 28.8%

The firm has a 50-day moving average of GBX 3.12 and a 200 day moving average of GBX 2.92. The stock has a market capitalization of £69.86 million, a price-to-earnings ratio of -1,570.67 and a beta of 1.53.

ImmuPharma (LON:IMM - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The company reported GBX (0.38) EPS for the quarter. ImmuPharma had a negative return on equity of 131.41% and a net margin of 3,519.56%. As a group, research analysts forecast that ImmuPharma plc will post -339.0000022 EPS for the current year.

About ImmuPharma

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.